MedTrace Logo

is the Sclerostin Marker of Chronic Periodontitis

NCT03639636 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-21

No results posted yet for this study

Summary

Reviewed literature suggests that sclerostin will inhibit the bone formation and ultimately leads to chronic periodontitis. Estimation of Sclerostin levels in the serum of periodontitis patients before and after intervention could explore the effectiveness of therapy and also give a more detailed insight into its diagnostic and prognostic potential as a biomarker of periodontal disease.

Conditions

  • Periodontitis

Interventions

OTHER

non surgical and surgical periodontal therapy

scaling and root planing periodontal flap surgery

Sponsors & Collaborators

  • Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre

    lead OTHER

Principal Investigators

  • Jammula surya prasanna, mds · panineeya institute of dental sciences and research center

Study Design

Purpose
SCREENING
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2017-12-20
Completion
2018-05-15

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03639636 on ClinicalTrials.gov